Bionano Genomics (BNGO) Change in Receivables (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Change in Receivables data on file, last reported at -$1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables rose 23.68% year-over-year to -$1.1 million; the trailing twelve-month figure through Mar 2026 stood at $779000.0 (up 117.19% YoY), and the FY2025 full-year result was $448000.0, up 110.82% from the prior year.
• Change in Receivables fell to -$1.1 million in Q1 2026, from $674000.0 in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $1.2 million in Q3 2022 to a low of -$2.1 million in Q2 2024.
• A 5-year average of -$12411.8 and a median of $141000.0 in 2025 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables jumped 611.46% in 2022 and plunged 347.6% in 2024, its largest moves.
• Tracing BNGO's Change in Receivables over 5 years: stood at $1.1 million in 2022, then slumped by 41.81% to $650000.0 in 2023, then plunged by 120.46% to -$133000.0 in 2024, then soared by 606.77% to $674000.0 in 2025, then slumped by 258.31% to -$1.1 million in 2026.
• Business Quant data shows BNGO's Change in Receivables at -$1.1 million in Q1 2026, $674000.0 in Q4 2025, and $1.0 million in Q3 2025.